Receive the latest updates from PMG.
Facebook Linked In Google Plus

Ohio Opioid Legislation Update

Date: September 24, 2014

If you have questions about how any of this legislation may affect your pain management program, please contact your RDO.

Ohio State Board of Pharmacy; Ohio Administrative Code Rule 4729-5-11

Effective April 1, 2015
All PMG clinics are exempt from this rule.

  • Requires responsible person on a category III terminal distributor of dangerous drugs with a pain management classification to be a physician authorized to practice medicine or surgery or osteopathic medicine and surgery and to meet one of several qualifications. Read more on the Ohio State Board of Pharmacy website.

House Bill (HB) 341: PASSED

Signed by Governor on June 16, 2014; effective September 16, 2014.

  • Requires providers to check OARRS before prescribing or dispensing Schedule II substances.
  • Requires an OARRS report on patients every 90 days.
  • Requires that certain prescribers and pharmacists, when renewing their professional licenses, certify to their licensing boards that they have access to OARRS. Subjects them to possible disciplinary action for false certifications.

HB 359: NO ACTION (by House Health Committee)

Direct Health Director to develop a one page informational document.

  • Would require all prescribers to give this document to any patient prescribed a Schedule II substance.


Signed by Governor on June 19, 2014; effective June 19 ,2104.

  • Requires consent of a parent/guardian for all minors before being prescribed a narcotic.


Medicaid was expanded through Controlling Board.

HB 332: NO ACTION (by House Health Committee)

  • Would require providers to have consult from a pain medicine specialist before prescribing narcotics to adults under 50 for chronic pain.

HB 501: NO ACTION (by House Health Committee)

  • Would make Zohydro a Schedule I substance.

HB 381: NO ACTION (by House Health Committee)

  • Would require an ID verification before pharmacy or licensed distributor dispenses a controlled substance and/or Tramadol.

HB 378: NO ACTION (by House Health Committee)

  • Would direct all providers to refer patients who are addicted to an addiction specialist before prescribing any medication containing buprenorphine, methadone, or naltrexone.


Passed House on April 9, 2014, was introduced in the Senate and is awaiting consideration in the Senate Finance Committee.

  • Directs all county ADAMHS boards to set up five factors of rehabilitation. Requires Medicaid Department to support.

Back to archives